Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa

Mette B Mønster, Nadja H Vissing, Henrik Schrøder, Dorthe Grosen, Steen Rosthøj, Niels Frimodt-Møller, Mikala Wang, Henrik C Schønheyder, Kjeld Schmiegelow, Ulrik S Justesen, Ulrikka Nygaard

2 Citations (Scopus)


Antimicrobial resistance in Pseudomonas aeruginosa is a threat to children with cancer. We explored the association between P. aeruginosa resistance and previous antibiotic exposure. All children with cancer and P. aeruginosa bacteremia in 2007 to 2016 in Denmark, a country with an overall resistance rate of ∼3%, were included. Twenty percent (10/49) of isolates from children previously exposed to meropenem were meropenem nonsusceptible. The only significant risk factor of meropenem nonsusceptibility was previous meropenem therapy (P=0.03). On the basis of these results, we suggest that meropenem should be reserved as a last resort for children with febrile neutropenia in countries with low antimicrobial resistance.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
Issue number8
Pages (from-to)e783-e787
Publication statusPublished - Nov 2020


  • Adolescent
  • Anti-Bacterial Agents/adverse effects
  • Child
  • Child, Preschool
  • Denmark/epidemiology
  • Febrile Neutropenia/drug therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Meropenem/adverse effects
  • Microbial Sensitivity Tests
  • Prognosis
  • Pseudomonas Infections/chemically induced
  • Pseudomonas aeruginosa/drug effects
  • Retrospective Studies
  • febrile neutropenia
  • antimicrobial resistance
  • empiric antibiotic therapy
  • infections


Dive into the research topics of 'Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this